Brief: Editas Medicine Announces First Quarter 2023 Results And Business Updates

Editas Medicine

05/05/2023 12:34

Editas Medicine Inc  EDIT.O :
    * EDITAS MEDICINE ANNOUNCES FIRST QUARTER 2023 RESULTS AND
BUSINESS UPDATES
    * ON TRACK TO DOSE 20 TOTAL PATIENTS BY YEAR-END IN RUBY
TRIAL
    * TO PROVIDE A CLINICAL UPDATE ON EDIT-301 PHASE 1/2 RUBY
TRIAL
FOR SCD IN JUNE
    * CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF
MARCH
31, 2023, WERE $401.8 MILLION
    * EXPECTS EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURES
INTO 2025
    * Q1 EARNINGS PER SHARE VIEW $-0.78 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3d2H28 
Further company coverage:  EDIT.O